CVS Health Down Nearly 8%, On Track for Largest Percent Decrease Since August 2023 — Data Talk
CVS Health Corporation (CVS) is currently at $73.36, down $6.20 or 7.79%
--Would be lowest close since Feb. 5, 2024, when it closed at $72.44
--On pace for largest percent decrease since Aug. 17, 2023, when it fell 8.14%
--Currently down two consecutive days; down 8.02% over this period
--Worst two day stretch since the two days ending Aug. 18, 2023, when it fell 8.13%
--Down 7.09% year-to-date
--Down 35.33% from its all-time closing high of $113.45 on July 29, 2015
--Down 3.78% from 52 weeks ago (April 4, 2023), when it closed at $76.25
--Down 9.89% from its 52-week closing high of $81.42 on Jan. 5, 2024
--Up 12.57% from its 52-week closing low of $65.17 on Aug. 31, 2023
--Traded as low as $73.15; lowest intraday level since March 1, 2024, when it hit $73.04
--Down 8.06% at today's intraday low; largest intraday percent decrease since Aug. 17, 2023, when it fell as much as 11.14%
--Second worst performer in the S&P 500 today
All data as of 9:53:34 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 02, 2024 10:10 ET (14:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters